FierceBiotech's subject line in today's e-mail for the report incorrectly identified Innate's partner in a new deal. The pact was inked with Bristol-Myers Squibb, as we report in the story, not Sanofi. We regret the error. Read the story
FierceBiotech's subject line in today's e-mail for the report incorrectly identified Innate's partner in a new deal. The pact was inked with Bristol-Myers Squibb, as we report in the story, not Sanofi. We regret the error. Read the story